Safety and immunogenicity of COVID‐19 vaccination in patients with hepatocellular carcinoma (CHESS‐NMCID 2101): A multicenter prospective study.

MLA

Qi, Xiaolong, et al. “Safety and Immunogenicity of COVID‐19 Vaccination in Patients with Hepatocellular Carcinoma (CHESS‐NMCID 2101): A Multicenter Prospective Study.” Journal of Medical Virology, vol. 94, no. 11, Nov. 2022, pp. 5553–59. EBSCOhost, https://doi.org/10.1002/jmv.27992.

APA

Qi, X., Wang, J., Zhang, Q., Ai, J., Liu, C., Li, Q., Gu, Y., Lv, J., Huang, Y., Liu, Y., Xu, D., Chen, S., Liu, D., Li, J., Xiang, H., Liang, J., Bian, L., Zhang, Z., Liu, L., & Zhang, X. (2022). Safety and immunogenicity of COVID‐19 vaccination in patients with hepatocellular carcinoma (CHESS‐NMCID 2101): A multicenter prospective study. Journal of Medical Virology, 94(11), 5553–5559. https://doi.org/10.1002/jmv.27992

Chicago

Qi, Xiaolong, Jitao Wang, Qiran Zhang, Jingwen Ai, Chuan Liu, Qianqian Li, Ye Gu, et al. 2022. “Safety and Immunogenicity of COVID‐19 Vaccination in Patients with Hepatocellular Carcinoma (CHESS‐NMCID 2101): A Multicenter Prospective Study.” Journal of Medical Virology 94 (11): 5553–59. doi:10.1002/jmv.27992.